Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Mutational analysis of CFTR in the Ecuadorian population using next-generation sequencing.

Ruiz-Cabezas JC, Barros F, Sobrino B, García G, Burgos R, Farhat C, Castro A, Muñoz L, Zambrano AK, Martínez M, Montalván M, Paz-Y-Miño C.

Gene. 2019 May 15;696:28-32. doi: 10.1016/j.gene.2019.02.015. Epub 2019 Feb 11.

PMID:
30763667
2.

Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders in Cystic Fibrosis Lung Transplant Recipients: A Case Series.

Mendogni P, Henchi S, Morlacchi LC, Tosi D, Nosotti M, Tarsia P, Gregorini AI, Rosso L.

Transplant Proc. 2019 Jan - Feb;51(1):194-197. doi: 10.1016/j.transproceed.2018.05.032. Epub 2018 Jun 30.

PMID:
30655153
3.

Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.

Skilton M, Krishan A, Patel S, Sinha IP, Southern KW.

Cochrane Database Syst Rev. 2019 Jan 7;1:CD009841. doi: 10.1002/14651858.CD009841.pub3.

PMID:
30616300
4.

Cystic fibrosis in Tunisian children: a review of 32 children.

Boussetta K, Khalsi F, Bahri Y, Belhadj I, Tinsa F, Messaoud TB, Hamouda S.

Afr Health Sci. 2018 Sep;18(3):664-670. doi: 10.4314/ahs.v18i3.24.

5.

Survival After Lung Transplant for Cystic Fibrosis in Italy: A Single Center Experience With 20 Years of Follow-up.

Savi D, Mordenti M, Bonci E, Troiani P, Giordani B, D'Alù V, Bertasi S, Cimino G, Rossi P, Poggi C, Palange P, Quattrucci S.

Transplant Proc. 2018 Dec;50(10):3732-3738. doi: 10.1016/j.transproceed.2018.08.020. Epub 2018 Sep 7.

PMID:
30577264
6.

The role of neonatal screening in nutritional evolution in the first 12 months after diagnosis of cystic fibrosis.

Martins JP, Forte GC, Simon MISDS, Epifanio M, Pinto LA, Marostica PJC.

Rev Assoc Med Bras (1992). 2018 Nov;64(11):1032-1037. doi: 10.1590/1806-9282.64.11.1032.

7.

Pulmonary aspiration in preschool children with cystic fibrosis.

Clarke D, Gorman I, Ringholz F, McDermott M, Cox DW, Greally P, Linnane B, Mc Nally P.

Respir Res. 2018 Dec 17;19(1):255. doi: 10.1186/s12931-018-0954-1.

8.

Recombinant growth hormone therapy for cystic fibrosis in children and young adults.

Thaker V, Carter B, Putman M.

Cochrane Database Syst Rev. 2018 Dec 17;12:CD008901. doi: 10.1002/14651858.CD008901.pub4.

PMID:
30557452
9.

Increasing Wellness Through Physical Activity in Children With Chronic Disease and Disability.

Coleman N, Nemeth BA, LeBlanc CMA.

Curr Sports Med Rep. 2018 Dec;17(12):425-432. doi: 10.1249/JSR.0000000000000548. Review.

PMID:
30531459
10.

Timing of dornase alfa inhalation for cystic fibrosis.

Dentice R, Elkins M.

Cochrane Database Syst Rev. 2018 Nov 12;11:CD007923. doi: 10.1002/14651858.CD007923.pub5.

PMID:
30480755
11.

How Do Youth with Cystic Fibrosis Perceive Their Readiness to Transition to Adult Healthcare Compared to Their Caregivers' Views?

Lapp V, Chase SK.

J Pediatr Nurs. 2018 Nov - Dec;43:104-110. doi: 10.1016/j.pedn.2018.09.012. Epub 2018 Sep 28.

PMID:
30473151
12.

Medications used in pediatric cystic fibrosis population.

Alves SP, Frank MA, Bueno D.

Einstein (Sao Paulo). 2018 Nov 8;16(4):eAO4212. doi: 10.31744/einstein_journal/2018AO4212. English, Portuguese.

13.

VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM; VX16-659-101 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.

PMID:
30334693
14.

VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.

PMID:
30334692
15.

Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review.

Dobra R, Edmondson C, Hughes D, Martin I, Davies JC.

Paediatr Drugs. 2018 Dec;20(6):555-566. doi: 10.1007/s40272-018-0315-z. Review.

PMID:
30328089
16.

Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population.

Polineni D, Piccorelli AV, Hannah WB, Dalrymple SN, Pace RG, Durie PR, Ling SC, Knowles MR, Stonebraker JR.

PLoS One. 2018 Oct 11;13(10):e0205257. doi: 10.1371/journal.pone.0205257. eCollection 2018.

17.

Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.

Sharma D, Xing S, Hung YT, Caskey RN, Dowell ML, Touchette DR.

Orphanet J Rare Dis. 2018 Sep 29;13(1):172. doi: 10.1186/s13023-018-0914-3.

18.

Evaluation of continuous constant current and continuous pulsed current in sweat induction for cystic fibrosis diagnosis.

Gomez CCS, Marson FAL, Servidoni MF, Ribeiro AF, Ribeiro MÂGO, Gama VAL, Costa ET, Ribeiro JD, Vieira Junior FU.

BMC Pulm Med. 2018 Sep 14;18(1):153. doi: 10.1186/s12890-018-0696-3.

19.

Dornase alfa for cystic fibrosis.

Yang C, Montgomery M.

Cochrane Database Syst Rev. 2018 Sep 6;9:CD001127. doi: 10.1002/14651858.CD001127.pub4. Review.

PMID:
30187450
20.

Effect of topiramate on sweat chloride level while screening for cystic fibrosis.

Siddaiah R, Thau E, Graff G.

BMJ Case Rep. 2018 Sep 5;2018. pii: bcr-2018-225697. doi: 10.1136/bcr-2018-225697.

PMID:
30185452

Supplemental Content

Loading ...
Support Center